Company Overview
Snapshot
Founded in December 2010 by Boaz Assaf, Colospan operates with 11–50 employees. The company has raised $17 million across 3 funding rounds from 6 investors. In June 2026, Colospan was acquired by Galmed Pharmaceuticals.
Business overview
Colospan is a clinical-stage medical device company focused on developing proprietary technology for colorectal surgery. Its core product is a single-use, temporary intraluminal bypass device, the CG-100, designed to prevent anastomotic leaks and divert colonic stomas by reducing contact between fecal matter and the anastomotic site. The company serves the healthcare industry, particularly surgeons and hospitals, operating within the Health Tech & Life Sciences sector, with a focus on medical devices and medical treatment & therapeutics.
Strategic signal
The acquisition of Colospan by Galmed Pharmaceuticals in June 2026 is a significant development, indicating a strategic move to create a GI-focused platform. This transaction highlights the value of Colospan's FDA Breakthrough Device-Designated technology and its active U.S. pivotal IDE trial, positioning the combined entity to address a substantial market in colorectal surgery.
Log in to access full profile ›Company Intelligence Q&A
- What was the most recent significant corporate event for Colospan?
- In June 2026, Colospan was acquired by Galmed Pharmaceuticals. This acquisition is intended to create a GI-focused platform, leveraging Colospan's FDA Breakthrough Device-Designated technology.
- When did Colospan receive FDA approval for its Intraluminal Bypass Device?
- Colospan announced FDA approval of its IDE for the Intraluminal Bypass Device in January 2020, positioning it as an alternative approach to diverting stoma.
- Which hospital was the first in the U.S. to test Colospan's CG-100 device?
- In December 2020, Henry Ford Hospital became the first in the U.S. to test Colospan's novel CG-100 Intraluminal Device in patients undergoing colorectal anastomosis.
- Did Colospan receive any grants from European organizations?
- In December 2021, Colospan received €8.2 million from the European Innovation Council for its novel colorectal surgery device.
- Who were some of the investors in Colospan's September 2017 funding round?
- In September 2017, Colospan received funding from investors including Anatomy Medical Technology Fund.